(Ketamine + midazolam) is under clinical development by Melt Pharmaceuticals and currently in Phase II for Sedation. According to GlobalData, Phase II drugs for Sedation have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Ketamine + midazolam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Ketamine + midazolam) overview
A fixed dose combination of ketamine and midazolam (MELT-100) is under development for the treatment of conscious sedation in medical procedures, pain and acute claustrophobia. The drug candidates are formulated as tablet and administered through sublingual route. Ketamine acts by targeting N-methyl-D-aspartate (NMDA) receptors and midazolam acts by targeting gamma-aminobutyric acid (GABA) A receptor. It is being developed based on Zydis delivery technology.
Melt Pharmaceuticals overview
Melt Pharmaceuticals is dedicated to the development of innovative approaches to procedural sedation and analgesia for short-term medical operations. The company is headquartered in United States.
For a complete picture of (Ketamine + midazolam)’s drug-specific PTSR and LoA scores, buy the report here.